270 related articles for article (PubMed ID: 34664162)
1. Niclosamide for Covid-19: bridging the gap.
Al-Kuraishy HM; Al-Gareeb AI; Alzahrani KJ; Alexiou A; Batiha GE
Mol Biol Rep; 2021 Dec; 48(12):8195-8202. PubMed ID: 34664162
[TBL] [Abstract][Full Text] [Related]
2. Niclosamide-A promising treatment for COVID-19.
Singh S; Weiss A; Goodman J; Fisk M; Kulkarni S; Lu I; Gray J; Smith R; Sommer M; Cheriyan J
Br J Pharmacol; 2022 Jul; 179(13):3250-3267. PubMed ID: 35348204
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
[TBL] [Abstract][Full Text] [Related]
4. Diacerein: A potential multi-target therapeutic drug for COVID-19.
de Oliveira PG; Termini L; Durigon EL; Lepique AP; Sposito AC; Boccardo E
Med Hypotheses; 2020 Nov; 144():109920. PubMed ID: 32534337
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).
Weiss A; Touret F; Baronti C; Gilles M; Hoen B; Nougairède A; de Lamballerie X; Sommer MOA
PLoS One; 2021; 16(12):e0260958. PubMed ID: 34855904
[TBL] [Abstract][Full Text] [Related]
6. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
7. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Ma Q; Pan W; Li R; Liu B; Li C; Xie Y; Wang Z; Zhao J; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Yang Z
Pharmacol Res; 2020 Aug; 158():104850. PubMed ID: 32360580
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV).
Siripongboonsitti T; Tawinprai K; Avirutnan P; Jitobaom K; Auewarakul P
J Infect Public Health; 2024 May; 17(5):897-905. PubMed ID: 38569269
[TBL] [Abstract][Full Text] [Related]
9. The role of berberine in Covid-19: potential adjunct therapy.
Babalghith AO; Al-Kuraishy HM; Al-Gareeb AI; De Waard M; Al-Hamash SM; Jean-Marc S; Negm WA; Batiha GE
Inflammopharmacology; 2022 Dec; 30(6):2003-2016. PubMed ID: 36183284
[TBL] [Abstract][Full Text] [Related]
10. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.
Wang ZZ; Li K; Maskey AR; Huang W; Toutov AA; Yang N; Srivastava K; Geliebter J; Tiwari R; Miao M; Li XM
FASEB J; 2021 Apr; 35(4):e21360. PubMed ID: 33749932
[TBL] [Abstract][Full Text] [Related]
11. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
Prabhakara C; Godbole R; Sil P; Jahnavi S; Gulzar SE; van Zanten TS; Sheth D; Subhash N; Chandra A; Shivaraj A; Panikulam P; U I; Nuthakki VK; Puthiyapurayil TP; Ahmed R; Najar AH; Lingamallu SM; Das S; Mahajan B; Vemula P; Bharate SB; Singh PP; Vishwakarma R; Guha A; Sundaramurthy V; Mayor S
PLoS Pathog; 2021 Jul; 17(7):e1009706. PubMed ID: 34252168
[TBL] [Abstract][Full Text] [Related]
12. Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.
Al-Kuraishy HM; Al-Gareeb AI; Negm WA; Alexiou A; Batiha GE
Inflammopharmacology; 2022 Oct; 30(5):1493-1501. PubMed ID: 35922738
[TBL] [Abstract][Full Text] [Related]
13. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
14. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.
Xia L; Shi Y; Su J; Friedemann T; Tao Z; Lu Y; Ling Y; Lv Y; Zhao R; Geng Z; Cui X; Lu H; Schröder S
Phytomedicine; 2021 May; 85():153390. PubMed ID: 33158717
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Landscape of Heparin Therapy for COVID-19.
Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y
Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
Brunaugh AD; Seo H; Warnken Z; Ding L; Seo SH; Smyth HDC
PLoS One; 2021; 16(2):e0246803. PubMed ID: 33571320
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Rana AK; Rahmatkar SN; Kumar A; Singh D
Cytokine Growth Factor Rev; 2021 Apr; 58():92-101. PubMed ID: 32948440
[TBL] [Abstract][Full Text] [Related]
19. A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine.
Paparo L; Maglio MA; Cortese M; Bruno C; Capasso M; Punzo E; Ferrucci V; Lasorsa VA; Viscardi M; Fusco G; Cerino P; Romano A; Troncone R; Zollo M
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164139
[TBL] [Abstract][Full Text] [Related]
20. Nitazoxanide and COVID-19: A review.
Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Batiha GE
Mol Biol Rep; 2022 Nov; 49(11):11169-11176. PubMed ID: 36094778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
